.beta.-sulfonyl hydroxamic acids
US5847153A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 19, 1997 |
| Grant date | Dec 8, 1998 |
| Priority date | — |
| Expiry date | Sep 19, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D233/72
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound of formula I ##STR1## or pharmaceutical acceptable salts thereof wherein R.sub.1 is C.sub.4-12 alkyl, C.sub.4-12 alkenyl, C.sub.4-12 alkynyl, --(CH.sub.2).sub.h -C.sub.3-8 cycloalkyl, --(CH.sub.2).sub.h -aryl, or --(CH.sub.2).sub.h -het; R.sub.2 is C.sub.1-12 alkyl, C.sub.2-12 alkenyl, C.sub.2-12 alkynyl, --(CH.sub.2).sub.h -C.sub.3-8 cycloalkyl, --(CH.sub.2).sub.h -C.sub.3-8 cycloalkenyl, --(CH.sub.2).sub.h -aryl, --(CH.sub.2).sub.h -het, --(CH.sub.2).sub.h -Q, --(CH.sub.2).sub.i -X-R.sub.4, or --(CH.sub.2).sub.i CHR.sub.5 R.sub.6. The compounds are inhibitors of matrix metalloproteinases involved in tissue degradation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.